Quick Answer
Atea Pharmaceuticals, Inc. reported Operating Income of -$180.89 million for fiscal year 2025.
Atea Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$180.89M | +6.3% |
| 2024 | -$192.95M | -17.5% |
| 2023 | -$164.16M | -25.7% |
| 2022 | -$130.65M | -194.4% |
| 2021 | $138.38M | +1354.6% |
| 2020 | -$11.03M | +24.5% |
| 2019 | -$14.61M | -54.1% |
| 2018 | -$9.48M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$45.57M | -22.5% | -10.2% |
| June 30, 2025 | -$41.34M | +11.9% | -5.9% |
| March 31, 2025 | -$39.04M | +44.1% | -4.9% |
| September 30, 2024 | -$37.20M | +8.8% | +20.7% |
| June 30, 2024 | -$46.92M | -33.2% | +32.8% |
| March 31, 2024 | -$69.81M | -67.9% | -71.2% |
| September 30, 2023 | -$40.78M | -150.5% | -15.8% |
| June 30, 2023 | -$35.23M | -9.1% | +15.2% |
- Atea Pharmaceuticals, Inc. showed an increase of +6.3% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Atea Pharmaceuticals, Inc.’s operating income has declined by 1808.7% (from -$9.48 million to -$180.89 million).
- The most recent figure is from Atea Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: